HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic

Reuters

2025/06/26

HOPE <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic

HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation $(TMS.AU)$.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2546780573"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546780573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546780573?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546780573","market":"fut","top_or_hot":-1,"title":"HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HOPE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation <a href=\"https://laohu8.com/S/TMS.AU\">$(TMS.AU)$</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-26 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      HOPE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation <a href=\"https://laohu8.com/S/TMS.AU\">$(TMS.AU)$</a>.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRXP\">NRX Pharmaceuticals Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL8cHBcw:1","article_id":"2546780573","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546780573","pubTimestamp":1750939399,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. , has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NRXP":"NRX Pharmaceuticals Inc."},"translate_title":"NRX Pharmaceuticals子公司HOPE Therapeutics将收购Cohen and Associates Clinic 49%的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9},"content_text":"HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic\n    \n\n        HOPE Therapeutics™, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), has announced the signing of a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC. This acquisition will see Cohen and Associates, a respected neuropsychiatry clinic in western Florida, become a foundational clinic for HOPE in the Sarasota-Bradenton area. The move is expected to immediately enhance both revenue and EBITDA for the company. Dr. Rebecca Cohen, founder of the clinic, expressed enthusiasm about the collaboration, emphasizing the shared commitment to delivering exceptional patient care. Cohen and Associates is renowned for offering a comprehensive range of treatments for conditions such as suicidal depression and PTSD, utilizing advanced therapies like ketamine, Spravato, and Transcranial Magnetic Stimulation $(TMS.AU)$.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL19345) on June 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}